CA3042808A1 - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents

Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Info

Publication number
CA3042808A1
CA3042808A1 CA3042808A CA3042808A CA3042808A1 CA 3042808 A1 CA3042808 A1 CA 3042808A1 CA 3042808 A CA3042808 A CA 3042808A CA 3042808 A CA3042808 A CA 3042808A CA 3042808 A1 CA3042808 A1 CA 3042808A1
Authority
CA
Canada
Prior art keywords
polypeptide
pharmaceutical composition
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3042808A
Other languages
English (en)
French (fr)
Inventor
Cynthia Lander
Colleen Brophy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of CA3042808A1 publication Critical patent/CA3042808A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3042808A 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition Abandoned CA3042808A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474370P 2011-04-12 2011-04-12
US61/474,370 2011-04-12
CA2832910A CA2832910C (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2832910A Division CA2832910C (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (1)

Publication Number Publication Date
CA3042808A1 true CA3042808A1 (en) 2012-10-18

Family

ID=47006527

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3042808A Abandoned CA3042808A1 (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CA2832910A Expired - Fee Related CA2832910C (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2832910A Expired - Fee Related CA2832910C (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Country Status (15)

Country Link
US (2) US9642888B2 (enExample)
EP (1) EP2696888B1 (enExample)
JP (1) JP6031510B2 (enExample)
KR (1) KR101862291B1 (enExample)
CN (3) CN108014340A (enExample)
AU (1) AU2012242768B2 (enExample)
BR (1) BR112013026313A8 (enExample)
CA (2) CA3042808A1 (enExample)
DK (1) DK2696888T3 (enExample)
ES (1) ES2711670T3 (enExample)
HK (1) HK1255005A1 (enExample)
MX (1) MX359516B (enExample)
RU (1) RU2620066C2 (enExample)
SG (2) SG10201604560TA (enExample)
WO (1) WO2012142320A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737145B2 (en) 2005-12-29 2010-06-15 Estrellita Pharmaceuticals, Llc Diamine derivatives as inhibitors of leukotriene A4 hydrolase
EP2617431B1 (en) 2007-01-10 2017-04-12 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
BRPI0922448A2 (pt) * 2008-12-10 2021-02-17 Purdue Research Foundation inibidor com base em peptídeo penetrante celular de quinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
ES2711670T3 (es) 2011-04-12 2019-05-06 Moerae Matrix Inc Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar
FR2976587B1 (fr) * 2011-06-20 2015-04-03 Basf Beauty Care Solutions F Methode de dosage in vitro par technique immunologique
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
EP2914269B1 (en) * 2012-10-31 2020-07-29 Galecto Biotech AB Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
MX2016011852A (es) * 2014-03-14 2017-05-09 Moerae Matrix Inc Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).
US10336788B2 (en) * 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
BR112017010238A2 (pt) 2014-11-17 2018-02-06 Moerae Matrix, Inc. composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular
MX2017008994A (es) * 2015-01-08 2018-09-18 Moerae Matrix Inc Formulacion de peptidos inhibidores mk2.
BR112017019343A2 (pt) 2015-03-12 2018-05-02 Moerae Matrix Inc uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
CN107987128B (zh) * 2017-11-17 2019-06-11 广东医科大学 一种功能多肽及其在制备防治肺纤维化药物中的应用
JP7471660B2 (ja) * 2018-05-17 2024-04-22 アクチュエイト セラピューティクス インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
USD958124S1 (en) 2019-12-16 2022-07-19 Samsung Electronics Co., Ltd. Television receiver
USD978094S1 (en) 2019-12-27 2023-02-14 Samsung Electronics Co., Ltd. Television receiver
US11744807B2 (en) * 2020-01-17 2023-09-05 Sami-Sabinsa Group Limited Therapeutic compositions and methods for pulmonary fibrosis
CN112386682B (zh) * 2020-02-12 2022-12-06 王斌 纤连蛋白在制备治疗新型冠状病毒肺炎药物中的应用
US20230127499A1 (en) * 2020-03-30 2023-04-27 Figene, Llc Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus
EP4142751A4 (en) * 2020-04-01 2025-01-08 Figene, LLC Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
US11505584B2 (en) * 2020-04-21 2022-11-22 Remodeless Cv Ltd Therapy for reducing brain damage
USD989726S1 (en) 2020-12-03 2023-06-20 Samsung Electronics Co., Ltd. Television receiver
USD989017S1 (en) 2020-12-03 2023-06-13 Samsung Electronics Co., Ltd. Television receiver
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
WO2022147172A1 (en) * 2020-12-30 2022-07-07 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions
WO2022204045A1 (en) * 2021-03-22 2022-09-29 Spiritus Therapeutics, Inc. Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo
CN113440431A (zh) * 2021-08-02 2021-09-28 山西锦波生物医药股份有限公司 重组ⅲ型人源化胶原蛋白在头皮护理中的用途及包含其的头皮护理产品
CN116262112A (zh) * 2021-12-14 2023-06-16 南京安吉生物科技有限公司 一种雾化吸入用融合多肽制剂及其制备方法和应用
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
CN114522221B (zh) * 2022-02-28 2024-04-19 中国人民解放军陆军特色医学中心 分泌蛋白ctgf在用于制备治疗急性肺损伤药物中的应用
WO2023178169A2 (en) * 2022-03-15 2023-09-21 Anemoi Biotech Holdings, Inc. Compositions and methods for treating the pathophysiology of severe viral infection
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用
CN117577330B (zh) * 2024-01-15 2024-04-02 北京大学 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
WO1993022443A1 (en) 1992-04-24 1993-11-11 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
KR100386337B1 (ko) 1993-12-09 2004-03-24 토마스 제퍼슨 대학교 진핵세포에서부위-특이적돌연변이를위한화합물과그방법
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
CA2367131C (en) 1999-04-05 2007-07-03 Solomon S. Steiner Methods for fine powder formation
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
EP3235384B1 (en) * 2003-11-25 2019-08-28 Virginia Tech Intellectual Properties, Inc. Composition for animal consumption
US20060074102A1 (en) * 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR20070057829A (ko) 2004-08-23 2007-06-07 맨카인드 코포레이션 포스포디에스테라아제 5형의 억제제의 폐 전달
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
MX2008012794A (es) * 2006-04-03 2008-10-15 Teva Pharma Microparticulas de farmacos.
EP2617431B1 (en) 2007-01-10 2017-04-12 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
US8063094B2 (en) 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2009085191A2 (en) * 2007-12-21 2009-07-09 Cabot Corporation Syntactic foam compositions, pipelines insulated with same, and method
DK2349310T3 (da) 2008-10-20 2014-08-11 Moerae Matrix Inc Polypeptid til behandling eller forebyggelse af adhæsioner
BRPI0922448A2 (pt) * 2008-12-10 2021-02-17 Purdue Research Foundation inibidor com base em peptídeo penetrante celular de quinases
US20110288036A1 (en) 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
ES2711670T3 (es) 2011-04-12 2019-05-06 Moerae Matrix Inc Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar

Also Published As

Publication number Publication date
WO2012142320A3 (en) 2015-06-11
JP6031510B2 (ja) 2016-11-24
AU2012242768A1 (en) 2013-10-24
DK2696888T3 (en) 2019-03-25
CN111110850A (zh) 2020-05-08
RU2620066C2 (ru) 2017-05-22
CN104302310A (zh) 2015-01-21
US20190022169A1 (en) 2019-01-24
MX2013011771A (es) 2014-07-30
SG10201604560TA (en) 2016-07-28
KR101862291B1 (ko) 2018-05-29
AU2012242768B2 (en) 2017-10-12
MX359516B (es) 2018-10-01
BR112013026313A8 (pt) 2018-01-30
JP2014533235A (ja) 2014-12-11
WO2012142320A2 (en) 2012-10-18
CA2832910A1 (en) 2012-10-18
EP2696888A4 (en) 2016-04-20
US20120263680A1 (en) 2012-10-18
KR20140063517A (ko) 2014-05-27
CA2832910C (en) 2019-07-02
CN108014340A (zh) 2018-05-11
ES2711670T3 (es) 2019-05-06
RU2013150249A (ru) 2015-05-20
HK1255005A1 (zh) 2019-08-02
EP2696888B1 (en) 2018-12-05
SG194135A1 (en) 2013-11-29
US9642888B2 (en) 2017-05-09
NZ616672A (en) 2016-04-29
BR112013026313A2 (pt) 2016-12-27
EP2696888A2 (en) 2014-02-19
WO2012142320A8 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
CA2832910C (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10500249B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10562947B2 (en) Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US20150258192A1 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)
HK1194983B (en) Compositions and methods for preventing or treating pulmonary fibrosis
NZ616672B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190509

FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831